(Q34842175)

4 August 2017

1 reference

title

Immunological weapons against acute myeloid leukaemia (English)

1 reference

4 August 2017

1 reference

1 reference

Joanna Galea-Lauri

1

1 reference

4 August 2017

publication date

1 September 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

107

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

20-27

1 reference

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Therapy of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Developmental approaches in immunological control of acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Immunotherapy of AML: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

The potential for antitumor vaccination in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Haematopoietic cell transplantation as immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Identical-twin bone marrow transplants for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Interleukin 2 and its receptors: recent advances and new immunological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

In vitro immune modulation by antibodies coupled to tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Streptavidin paramagnetic particles provide a choice of three affinity-based capture and magnetic concentration strategies for retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells hold promise for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells: a novel therapeutic modality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Feeding dendritic cells with tumor antigens: self-service buffet or à la carte?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells: at the clinical crossroads

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cell vaccination for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Dendritic cells as adjuvants for immune-mediated resistance to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01497.X

Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

The role of chromosome translocations in leukemogenesis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Molecular evaluation of acute myeloid leukemias

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Dendritic cells: unique leukocyte populations which control the primary immune response

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Novel costimulators in the immune gene therapy of cancer

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Role of B7-1 in mediating an immune response to myeloid leukemia cells.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782763

The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia

26 October 2018

1 reference

12 December 2020

Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines

1 reference

12 December 2020

Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression

1 reference

12 December 2020

Autoimmune disease induced by dendritic cell immunization against leukemia

1 reference

12 December 2020

Use of interleukin-2 in the management of haematological malignancies: focus on minimal residual disease

1 reference

12 December 2020

Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias

1 reference

12 December 2020

Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways

1 reference

12 December 2020

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia

1 reference

12 December 2020

Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia

1 reference

12 December 2020

Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-alpha treatment

1 reference

12 December 2020

CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells

1 reference

12 December 2020

Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients

1 reference

12 December 2020

Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells

1 reference

12 December 2020

Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells

1 reference

12 December 2020

Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission

1 reference

12 December 2020

Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses

1 reference

12 December 2020

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

12 December 2020

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

12 December 2020

Interleukin-12: a cytokine at the interface of inflammation and immunity

1 reference

12 December 2020

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes

1 reference

12 December 2020

Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia

1 reference

12 December 2020

Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture

1 reference

12 December 2020

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

12 December 2020

Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia

1 reference

12 December 2020

Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy

1 reference

12 December 2020

10.1046/J.1365-2567.2002.01497.X

Identifiers

DOI

1 reference

4 August 2017

0 references

1 reference